== Enrollment flow diagram

== Enrollment flow diagram. Following screening and consent, a blood sample was drawn. and cell-based A/H3N2 strains were conducted. The primary outcome measure was seroconversion (day 28/day 0 titer ratio 4 with day 28 titer 40). Secondary outcomes were elevated titers (day 28 HI titer 1:110), geometric mean titers (GMTs) and mean fold rise (MFR) in titers. Outcomes were compared for 74 ccIIV4 recipients and 70 IIV4 recipients, and for those vaccinated and unvaccinated the previous year. Only the HI and MN laboratory analysis team was blinded to group assignment. == Results: == In this racially diverse (81% non-white) group of children with a median age of 14 years, baseline Maxacalcitol demographics did not differ between vaccine groups. At day 0, half or more in each vaccine group had elevated HI or MN titers. Low seroconversion rates (14%35%) were found; they did not differ between groups. Among 201819 ccIIV4 recipients, those unvaccinated in the previous season showed significantly higher MFR against A/H1N1 and A/H3N2 cell-grown virus than the previously vaccinated. Comparable results were found for MFR against B/Victoria among 20182019 IIV4 recipients. == Maxacalcitol Conclusion: == In mostly older children with high baseline titers, no differences in seroconversion or other measures of antibody titers were found between ccIIV4 and IIV4 recipients against egg- and cell-grown influenza vaccine viruses. Keywords:Immunogenicity, RCT, Influenza, Vaccine, Children, Adolescents == 1. Introduction == In response to variable vaccine effectiveness and improvements in biotechnology, the types of influenza vaccines available, licensed and recommended for use, and some of the formulations of those vaccines have been changing with increasing rapidity. Furthermore, viral mutations either naturally occurring in the community, such as the significant genetic drift of 20142015 [1], or as a result of the manufacturing process have been documented. Increasing glycosolation of the wild influenza virus over time has reduced effectiveness of vaccines grown in eggs in general, and certain mutations, such as T160K, have markedly reduced the protection from egg-derived vaccines [2]. Of clinical significance, Chen et al. (2019), found a strong unfavorable correlation between passage of A/H3N2 viruses in eggs and vaccine efficacy [3]. Thus, measuring the immune response to new vaccine formulations and comparing them with older, widely-used vaccines are warranted. Furthermore, the immunological responses to new and reformulated vaccines across population subgroups and in the context of influenza vaccination Maxacalcitol history have not been thoroughly explored. While older adults are the group most susceptible to influenza-related morbidity and mortality [4], children are of particular interest because there is evidence that they serve as the major mode of influenza disease transmission in communities [5]. Moreover, they have the advantages of relatively short vaccination histories, and typically robust immune systems [5]. Thus, a study of immune response of children who were vaccinated two years in a row, compared with those without vaccination in Rabbit Polyclonal to TSPO the previous season may increase our understanding of repeated vaccination. The purpose of this study was to compare serological responses of a racially diverse group of healthy children 420 years of age receiving ccIIV or egg-based quadrivalent influenza vaccine (IIV4) in the 20182019 influenza vaccination season. 20172018 was the first season in which one vaccine was manufactured which substituted an A/H3N2 strain grown using a non-egg, cell-based process (ccIIV) for the standard egg-based A/H3N2 strain while maintaining the A/H1N1 strain and B lineages grown in eggs. Maxacalcitol In 20182019, the ccIIV4 included three cell-based seed strains, namely B/Yamagata, B/Victoria and A/H3N2; A/H1N1 was still derived from an egg-based seed, leading to a 3:1 formulation. Antibody titers were measured in participants who were known to have received no vaccine or had received the standard egg-based inactivated influenza vaccine in the previous season (20172018). We hypothesized that there would be no difference in immunological response between the two vaccines with respect to A/H1N1, but that there would be a difference between the two.